Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 2/20 | 0.45 |
| ▸ | CASP1 | P29466 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | CASP7 | P55210 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ADA | P00813 | 5/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL872184 | 0.83 | ADA (0.46) | KDM4EALDH1A1MAPTHPGDGAA | |
| SCHEMBL872083 | 0.81 | PDE5A (0.45) | KDM4EALDH1A1MAPTGAAKMT2A | |
| SCHEMBL27932435 | 0.76 | ADORA2A (0.42) | KDM4EALDH1A1MAPTHPGDGAA | |
| SCHEMBL881892 | 0.76 | ADA (0.47) | KDM4EALDH1A1MAPTHPGDGAA | |
| SCHEMBL872739 | 0.76 | PDE5A (0.47) | KDM4EALDH1A1MAPTGAAKMT2A | |
| SCHEMBL15261376 | 0.75 | ADA (0.47) | KDM4EALDH1A1KMT2AHTTMEN1 | |
| SCHEMBL10258583 | 0.73 | ADA (0.42) | ALDH1A1MAPTGAAKMT2AMEN1 | |
| SCHEMBL15277465 | 0.72 | ADORA2A (0.60) | ADORA2A | |
| SCHEMBL15261779 | 0.71 | ADA (0.44) | KDM4EALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL15261839 | 0.71 | ADA (0.42) | ALDH1A1ADASMN1; SMN2ADORA2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619211-B1 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS LTD (IN) | 2015-09-09 | — | — | EP | disclosed |
| EP-2619211-B1 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS LTD (IN) | 2015-09-09 | — | — | EP | disclosed |
| US-9006177-B2 | Fused tricyclic compounds as adenosine receptor antagonist | ADVINUS THERAPEUTICS LIMITED (IN) | 2015-04-14 | — | — | US | disclosed |
| US-9006177-B2 | Fused tricyclic compounds as adenosine receptor antagonist | ADVINUS THERAPEUTICS LIMITED (IN) | 2015-04-14 | — | — | US | disclosed |
| US-20130252885-A1 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-09-26 | — | — | US | disclosed |
| US-20130252885-A1 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-09-26 | — | — | US | disclosed |
| EP-2619211-A2 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | Advinus Therapeutics Private Limited (IN) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012038980-A2 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252885-A1 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADORA2A, ADORA2B, ADORA1 | KDM4E 4233/4885ALDH1A1 2343/4885MAPT 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.